Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations

Simply Wall St · 05/08 10:12

Arcus Biosciences (NYSE:RCUS) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$28.0m (down 81% from 1Q 2024).
  • Net loss: US$112.0m (loss widened by US$108.0m from 1Q 2024).
  • US$1.14 loss per share (further deteriorated from US$0.046 loss in 1Q 2024).
Our free stock report includes 2 warning signs investors should be aware of before investing in Arcus Biosciences. Read for free now.
earnings-and-revenue-growth
NYSE:RCUS Earnings and Revenue Growth May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Arcus Biosciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 27%. Earnings per share (EPS) also missed analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 8.5% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Arcus Biosciences, and understanding these should be part of your investment process.